Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co Capital Intensity

The Capital Intensity Ratio of Shanghai Rendu Biotechnology Co (688193.SS) as of Oct 28, 2026 is 611.43 %. In the previous year, Capital Intensity Ratio was 560.67 % — a change of 9.05% (higher).

Capital Intensity

611.43 %

YoY

9.05%

Last updated:

Capital Intensity Ratio of Shanghai Rendu Biotechnology Co is 2025 611.43 % . Capital Intensity Ratio of Shanghai Rendu Biotechnology Co was 2024 560.67 % . It decreases by 9.05% higher compared to the previous year.

The Shanghai Rendu Biotechnology Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
243.03 CNY
Jan 1, 2019
188.64 CNY
Jan 1, 2020
124.36 CNY
Jan 1, 2021
129.52 CNY
Jan 1, 2022
358.31 CNY
Jan 1, 2023
641.51 CNY
Jan 1, 2024
560.67 CNY
Jan 1, 2025
611.43 CNY
The Shanghai Rendu Biotechnology Co Capital Intensity history
YEARCapital IntensityYoY
611.43 %+9.05%
560.67 %-12.60%
641.51 %+79.04%
358.31 %+176.64%
129.52 %+4.15%
124.36 %-34.07%
188.64 %-22.38%
243.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co., Ltd. generates revenue through the sale of molecular diagnostic tests and medical instruments. The company develops diagnostic reagents using RNA isothermal amplification technology, including respiration series, reproduction series, enterovirus series, and blood-borne diseases series. These products are sold domestically within China, targeting healthcare providers and laboratories that require rapid and accurate diagnostic solutions. The firm's focus on domestic market sales ensures consistent demand for its specialized reagents and instruments. The company's product portfolio includes multiple series of diagnostic reagents designed for specific health conditions, such as respiratory and reproductive health. Medical instruments are also manufactured and sold alongside these reagents. Domestic sales within China form the primary revenue stream, with no mention of international markets or additional product lines. The firm's technology and product offerings cater to the needs of medical professionals seeking efficient diagnostic tools. Shanghai Rendu Biotechnology's business model relies on the domestic market for all product sales, with no indication of export or international partnerships. The company's workforce of 528 full-time employees supports the development, manufacturing, and sales of its diagnostic reagents and instruments. Revenue is derived solely from the sale of these products within China, without any reference to third-party collaborations or additional services. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Capital Intensity Ratio of Shanghai Rendu Biotechnology Co is 611.43 % in 2025.

Capital Intensity Ratio of Shanghai Rendu Biotechnology Co changed from 560.67 % to 611.43 %, representing a 9.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Shanghai Rendu Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Shanghai Rendu Biotechnology Co

All Key Metrics — Shanghai Rendu Biotechnology Co